"id","rationale","versionIdentifier","instanceType","uuid:ID"
"StudyVersion_1","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","2","StudyVersion","7ffcf93a-b0fc-4ba2-9ebd-0e55264020c5"
